Provera and Embolism venous - a phase IV clinical study of FDA data

Summary:

Embolism venous is reported as a side effect among people who take Provera (medroxyprogesterone acetate), especially for people who are female, 60+ old, have been taking the drug for 2 - 5 years also take Premarin, and have Heavy or prolong menstrual bleeding.

The phase IV clinical study analyzes which people have Embolism venous when taking Provera. It is created by eHealthMe based on reports of 53,365 people who have side effects when taking Provera from the FDA, and is updated regularly.

What is Provera?

Provera has active ingredients of medroxyprogesterone acetate. It is often used in birth control. eHealthMe is studying from 54,943 Provera users. Check the latest studies of Provera.

What is Embolism venous?

Embolism venous (embolus may pass into the arterial system) is found to be associated with 302 drugs and 394 conditions by eHealthMe. Check the latest studies of Embolism venous.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

53,365 people reported to have side effects when taking Provera.
Among them, 17 people (0.03%) have Embolism venous.

Among these 17 people:

How long have people been on Provera when they have Embolism venous? *

What is the gender of people who have Embolism venous when taking Provera? *

female: 100 %
male: 0.0 %

What is the age of people who have Embolism venous when taking Provera? *

What are other drugs people take besides Provera? *

Prempro: 13 people, 76.47%
Premarin: 13 people, 76.47%
Cycrin: 3 people, 17.65%
Premphase: 1 person, 5.88%
Nuvaring: 1 person, 5.88%

What are other side effects people have besides Embolism venous? *

Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 14 people, 82.35%
Heart Attack: 13 people, 76.47%
Dementia (madness): 13 people, 76.47%
Breast Cancer Female: 12 people, 70.59%
Transient Ischaemic Attack (a transient episode of neurologic dysfunction caused by ischemia (loss of blood flow)): 1 person, 5.88%
Pulmonary Infarction (death of a small area of lung): 1 person, 5.88%
Pulmonary Embolism (blockage of the main artery of the lung): 1 person, 5.88%
Ovarian Cysts (fluid filled sacs of the ovary): 1 person, 5.88%
Gestational Diabetes (diabetes in pregnancy): 1 person, 5.88%
Dysfunctional Uterine Bleeding (Dub): 1 person, 5.88%

What are the existing conditions these people have? *

Oligomenorrhea: 1 person, 5.88%
Heavy Or Prolong Menstrual Bleeding: 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Provera and have Embolism venous?

- Check whether Embolism venous is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Provera:

Provera (54,943 reports)

Embolism venous treatments and more:

Embolism venous (12,049 reports)

Browse all side effects of Provera:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Embolism venous:

Embolism venous (302 drugs)

Browse all the conditions that are associated with Embolism venous:

Embolism venous (394 conditions)

Related publications that referenced our studies

Bahall M, Reyes AJ, Ramcharan K, Hosein N, Seegobin K, Bahall K, Sharma H, Dhansingh S, Mahabir A, "Neuro-ophthalmological manifestations after intramuscular medroxyprogesterone: a forme fruste of idiopathic intracranial hypertension?", Neurology international, 2016 Sep .
Bahall M, Reyes AJ, Ramcharan K, Hosein N, Seegobin K, Bahall K, Sharma H, Dhansingh S, Mahabir A, "Neuro-ophthalmological manifestations after intramuscular medroxyprogesterone: a forme fruste of idiopathic intracranial hypertension?", Neurology international, 2016 Sep .

How the study uses the data?

The study uses data from the FDA. It is based on medroxyprogesterone acetate (the active ingredients of Provera) and Provera (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.